Terlipressin Hrs denied as non-formulary by Humana?

Humana's specific coverage criteria for terlipressin hrs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Terlipressin as Non-Formulary — and What to Do

Terlipressin is an FDA-approved intravenous therapy for hepatorenal syndrome type 1 (HRS-1). A non-formulary denial from Humana means the drug is not included on the plan's approved drug list at a covered tier — or is excluded entirely — and therefore requires a specific exception process before the plan will pay for it.

### Why This Denial Happens

Formulary placement is a business and clinical decision made by Humana's pharmacy and therapeutics committee. Newer FDA approvals for rare or specialty conditions are sometimes not added to formulary promptly, or they may be placed on a tier requiring prior authorization plus a formulary exception. Because HRS-1 is a relatively rare condition, terlipressin may not yet be included or may be on a restricted tier.

### Why It's Appealable

All commercial plans regulated under the ACA must have a formulary exception process. You have the right to request a medical exception, and if denied, to appeal. Plans must cover a non-formulary drug when the formulary alternatives are not clinically appropriate for the member. Under ACA §2719 and ERISA §503, a formulary exception denial is subject to full internal review and then independent external review. File the external-review request within approximately four months of the denial. Expedited review is available when the clinical situation is urgent.

### Concrete Appeal Process

1. Formulary exception request — File this simultaneously with or before the formal appeal. Your prescriber certifies that the formulary alternatives are clinically inadequate for this patient. 2. Identify formulary alternatives — Obtain Humana's list of covered alternatives for HRS in writing; document in the prescriber's letter why each is not appropriate. 3. Internal appeal — Submit within the deadline on the denial letter with a full documentation package. 4. External review — Request independent review if the formulary exception and internal appeal are both denied.

### Documentation to Gather

• Diagnosis confirmation — hepatologist or intensivist chart notes documenting HRS-1 consistent with the FDA-approved indication.
• Formulary-alternative assessment — prescriber documentation noting each formulary alternative Humana offers and the specific clinical reason it is not appropriate for this patient.
• Clinical severity — objective chart findings reflecting the acuity and urgency of the patient's condition.
• Medical-necessity letter — a letter from the treating physician explaining why terlipressin is medically necessary and why formulary alternatives are insufficient, referencing the applicable professional society guideline (such as AASLD guidance on HRS management).

### Criteria-Mapping Structure

Retrieve Humana's formulary exception criteria and list each one in a table. For each criterion — such as "formulary alternative is contraindicated," "patient tried and failed the formulary alternative," or "formulary alternative is clinically inappropriate" — insert the specific chart fact and prescriber statement that addresses it. An exception request that maps directly to the plan's own stated criteria is far more likely to succeed than a general letter. Attach the FDA prescribing label as confirmation of the approved indication.